Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluvastatin · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Fluvastatin | DRUG | - |
| fluvastatin, ezetimibe | DRUG | - |
Inclusion Criteria: * Mixed dyslipidemia * Primary hypercholesterolemia Exclusion Criteria: * Pregnant or lactating women * Age \> 18 years Other protocol-defined inclusion and exclusion criteria may apply.
Top 7 of 10 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Enlicitide |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran, Muvalaplin |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE3 | Pelacarsen |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | Obicetrapib |
| AstraZeneca PLC | AZN | 2 | PHASE2 | Rosuvastatin, AZD0780, AZD4954 |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
Fluvastatin is a small molecule HMGCR inhibitor developed by Novartis AG (ticker NVS). It is being studied in Phase 3 clinical development for dyslipidemia, heterozygous familial hypercholesterolemia, and mixed dyslipidemia. It is an investigational therapy in the cardiovascular therapeutic area.
Fluvastatin is being evaluated for the treatment of dyslipidemia, heterozygous familial hypercholesterolemia, and mixed dyslipidemia. These are lipid disorders characterized by abnormal cholesterol levels. The clinical program includes adult and pediatric populations, with trials conducted in Spain, Switzerland, and China.
Fluvastatin targets HMGCR, also known as HMG-CoA reductase. It acts as an inhibitor of this enzyme, which is the rate-limiting step in cholesterol biosynthesis. By inhibiting HMGCR, fluvastatin reduces cholesterol production in the body.
Fluvastatin is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical development program for fluvastatin in dyslipidemia and related lipid disorders.
Fluvastatin is in Phase 3 clinical development. All three registered trials are Phase 3 studies, and all have completed. The program has enrolled a total of 325 participants across the trials, which were conducted in Spain, Switzerland, and China.
Fluvastatin has been studied in three completed Phase 3 trials: NCT00171288, which compared fluvastatin plus ezetimibe versus fluvastatin alone in dyslipidemia; NCT00171236, in children with heterozygous familial hypercholesterolemia; and NCT00136799, which evaluated different fluvastatin doses in adults with mixed dyslipidemia or primary hypercholesterolemia.
No, fluvastatin and ezetimibe are different compounds. Fluvastatin is an HMGCR inhibitor, while ezetimibe is a separate cholesterol-lowering agent. One Phase 3 trial, NCT00171288, evaluated fluvastatin and ezetimibe in combination compared with fluvastatin alone in patients with dyslipidemia.